Viatris Stock (VTRS)

XNGS Alert Compare

Health Care · Fundamental analysis

· How we analyze

Metrics from daily candles, as of Nov 20, 2026 · Extended universe

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

Viatris was formed in 2020 through the merger of Mylan and Pfizer’s Upjohn division. The company mainly makes generic drugs and well-known brand-name drugs such as Lipitor and Viagra. It sells in a great many countries. As of Oct 11, 2026

Fact sheet (from the annual report) Pharmaceutical manufacturers · Canonsburg, USA

Viatris is a global healthcare company with generics including complex products, well-known brand-name medicines and a growing range of new medicines. Brand-name medicines also include over-the-counter products, which consumers obtain without a prescription and without reimbursement, mostly through pharmacies, drugstores and supermarkets. As complex generics, the report names Breyna, Wixela Inhub and an injectable glatiramer acetate product, for example. Customers include retail and pharmacies, wholesalers and distributors, payers, insurers, governments and institutions such as hospitals. The reporting segments are called Developed Markets, Greater China, JANZ and Emerging Markets.

Automatically summarized from SEC annual report (10-K, filed Feb 26, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today −1.3%
  • 7 days −5.7%
  • 30 days +6.4%
  • 1 year +92.6%
Day range (last trading day)
−1.0%Price at 30% of the range+2.4%
52-week range
−48.3%Price at 86% of the range+8.0%
Distance from the all-time high
−74.4%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Fundamentals · Analysis method

Growth, margin, balance sheet, cash flow and dividend compared with the sector – with traffic lights and quality checks in the fundamental analysis. To the fundamental analysis

Fundamental analysis

Viatris · Sector Health Care · amounts in USD

Source: SEC filings, As of Feb 26, 2026.

For you first Dividend

The dividend per share was never cut as far as our annual data goes (4 years in a row).

Years without a cut
at least 4
as far as the data goes

For you first Valuation

There is no comparison for the P/E: the last fiscal year ended with a loss.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
0 of 6
criteria with data met
Revenue per year (5 y)
+3.7%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
3 of 8
criteria with data met
Net margin
−24.6%
Return on equity
−23.9%

For you first Trading

The overview of this stock shows the trend by timeframe.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality 3 of 8 met

  • not met: Gross margin above 40% 35.1%
  • not met: Operating margin above 15% −18.6%
  • not met: Net margin above 10% −24.6%
  • not met: Return on equity above 15% −23.9%
  • met: Free cash flow margin above 10% 13.5%
  • not met: Profit in each of the last 5 fiscal years 2 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • met: Equity ratio above 30% 39.6%
Gross margin

35.1% Fiscal year 2025

Rank 30 of 100: higher than 30% of 370 peers (All). weak.

Rank 21 of 100: higher than 21% of 49 peers (Sector). weak.

Median Health Care: 61.8%

Share of revenue left after the direct cost of the products sold.

Operating margin

−18.6% Fiscal year 2025

Rank 8 of 100: higher than 8% of 470 peers (All). weak.

Rank 6 of 100: higher than 6% of 54 peers (Sector). weak.

Median Health Care: 17.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

−24.6% Fiscal year 2025

Rank 6 of 100: higher than 6% of 584 peers (All). weak.

Rank 6 of 100: higher than 6% of 63 peers (Sector). weak.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

−23.9% Fiscal year 2025

Rank 5 of 100: higher than 5% of 544 peers (All). weak.

Rank 6 of 100: higher than 6% of 54 peers (Sector). weak.

Median Health Care: 12.8%

Net income divided by equity at fiscal year end.

Return on assets

−9.5% Fiscal year 2025 (total assets at year end)

Rank 5 of 100: higher than 5% of 594 peers (All). weak.

Rank 6 of 100: higher than 6% of 63 peers (Sector). weak.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

39.6% Fiscal year 2025

Rank 55 of 100: higher than 55% of 595 peers (All). medium.

Rank 42 of 100: higher than 42% of 63 peers (Sector). medium.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

13.5% Fiscal year 2025

Rank 56 of 100: higher than 56% of 465 peers (All). medium.

Rank 43 of 100: higher than 43% of 61 peers (Sector). medium.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

1.9B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 0 of 6 met · 1 without data

  • not met: Over 3 years, revenue grew by more than 5% per year −4.2%
  • not met: Over 5 years, revenue grew by more than 5% per year +3.7%
  • no data: Over 10 years, revenue grew by more than 5% per year no comparable figures over 10 years
  • not met: Over 3 years, EPS grew by more than 5% per year no earnings per share in the last fiscal year
  • not met: Over 5 years, EPS grew by more than 5% per year no earnings per share in the last fiscal year
  • not met: Revenue rose in at least 4 of the last 5 fiscal years 1 of 5
  • not met: Revenue rose in the last fiscal year −3.0%
Revenue growth 3 years

−4.2% per year

Rank 10 of 100: higher than 10% of 578 peers (All). weak.

Rank 10 of 100: higher than 10% of 62 peers (Sector). weak.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+3.7% per year

Rank 19 of 100: higher than 19% of 549 peers (All). weak.

Rank 19 of 100: higher than 19% of 60 peers (Sector). weak.

Median Health Care: +7.8%

Average growth per year over 5 fiscal years.

Dividend 4 of 5 met · 2 without data

  • met: Pays a dividend 0.48 USD
  • not met: Payout ratio at most 60% of earnings despite a loss
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • no data: Dividend per share higher than 5 years ago no comparable dividend 5 years ago
  • no data: Free cash flow per share covers the dividend not stated in the SEC filings
  • met: Dividends paid over the last 5 years covered by free cash flow 24% of free cash flow

Financial strength 4 of 6 met

  • not met: Piotroski F-Score at least 7 of 9 4 of 8 · 1 without data
  • met: Long-term debt no higher than equity 0.85
  • met: Current assets cover current liabilities 1.38
  • met: Positive equity 14.7B USD
  • not met: In 5 years, share count up by at most 5% +133.7%
  • met: Free cash flow positive in the last fiscal year 1.9B USD
Piotroski F-Score

4 of 8 Fiscal year 2025

No rank: not all 9 criteria have data.

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.85 at fiscal year end

Rank 38 of 100: lower than 38% of 486 peers (All). medium.

Rank 25 of 100: lower than 25% of 50 peers (Sector). weak.

Median Health Care: 0.66

Long-term financial debt divided by equity.

Liquidity (current ratio)

1.38 at fiscal year end

Rank 53 of 100: higher than 53% of 513 peers (All). medium.

Rank 39 of 100: higher than 39% of 63 peers (Sector). medium.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

+133.7% in 5 years

Rank 3 of 100: lower than 3% of 507 peers (All). weak.

Rank 3 of 100: lower than 3% of 59 peers (Sector). weak.

Median Health Care: −4.3%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • not met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • not met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • met: Long-term debt relative to total assets fell
  • not met: Liquidity (current assets / current liabilities) rose
  • no data: No additional shares (diluted share count did not rise)
  • not met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light yellow: Revenue grew over 5 years (+3.7% per year), more slowly than the sector median.
  • Light red: Loss in the last fiscal year.
  • Light yellow: Debt higher than usual in the sector.
  • Light red: Profit in 4 of 8 fiscal years.
  • Light red: Dividend higher than earnings.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 11.4B USD · Net income 352.5M USD · Net margin 3.1%
  2. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 11.5B USD · Net income 16.8M USD · Net margin 0.1%
  3. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 11.9B USD · Net income −669.9M USD · Net margin −5.6%
  4. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 17.9B USD · Net income −1.3B USD · Net margin −7.1%
  5. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 16.3B USD · Net income 2.1B USD · Net margin 12.8%
  6. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 15.4B USD · Net income 54.7M USD · Net margin 0.4%
  7. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 14.7B USD · Net income −634.2M USD · Net margin −4.3%
  8. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 14.3B USD · Net income −3.5B USD · Net margin −24.6%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 14.3B USD · Net income −3.5B USD · Net margin −24.6%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Sep 2026 −0.3% vs. the same quarter a year earlier.

Revenue 12 months vs. prior 12
+4.3%
12 months: 14.7B USD · Fiscal year 2025: −3.0%
Net margin 12 months
–
Fiscal year 2025: −24.6%
Free cash flow margin 12 months
14.3%
Fiscal year 2025: 13.5%
More depth

Calculation of the 12 months to Sep 30, 2026

  • Revenue: fiscal year to Dec 31, 2025 14.3B USD + year to date to Sep 30, 2026 11.0B USD − same period a year earlier to Sep 30, 2025 10.6B USD = 14.7B USD
  • Operating cash flow: fiscal year to Dec 31, 2025 2.3B USD + year to date to Sep 30, 2026 1.7B USD − same period a year earlier to Sep 30, 2025 1.5B USD = 2.5B USD
  • Capital expenditure: fiscal year to Dec 31, 2025 378.8M USD + year to date to Sep 30, 2026 178.4M USD − same period a year earlier to Sep 30, 2025 182.3M USD = 374.9M USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
Jul–Sep 263.7B−0.3%––
Apr–Jun 263.8B+4.9%––
Jan–Mar 263.5B+8.1%––
Oct–Dec 25*3.7B+5.0%––
Jul–Sep 253.8B+0.2%––
Apr–Jun 253.6B−5.6%––
Jan–Mar 253.3B−11.2%––
Oct–Dec 24*3.5B−8.1%––

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

As of: 12 months to Sep 30, 2026, filed on Nov 5, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

There was no profit in fiscal year 2025; operating income does not cover interest.

Cash flow ÷ profit
–
no profit in fiscal year 2025
Interest coverage
negative
operating income negative · 3 years: negative
Tax rate
–
no profit before tax
More depth

Calculation for fiscal year 2025

  • Operating cash flow 2.3B USD ÷ Net income −3.5B USD = no ratio (no profit)
  • Operating income −2.7B USD ÷ Interest expense 471.3M USD = negative
  • Taxes −150.1M USD ÷ profit before tax −3.7B USD = no rate (no profit before tax)
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
2025–negative–
2024–0.0x–
2023over 10x1.3x73.0%
20221.42x2.7x26.1%
2021–negative–

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2025 · Source: SEC filings

How even were the last years?

Consistency

In 8 fiscal years 4 loss years; 4 years with lower revenue across 7 years with a prior-year figure.

Loss years
4 of 8
net income below zero
Years with lower revenue
4 of 7
revenue below the prior year
Net margin range
37.4 percentage points
from −24.6% to 12.8%
Net margin by fiscal year · ▾ revenue below the prior year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2025−3.0%−24.6%
2024−4.5%−4.3%
2023−5.1%0.4%
2022−9.1%12.8%
2021+49.7%−7.1%
2020+3.9%−5.6%
2019+0.6%0.1%
2018–3.1%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2018–2025 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 35.1 USD gross profit remained.

Operating loss: −18.6% of revenue

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue14.3B USD100.0%
Gross profit5.0B USD35.1%
Cost of revenue9.3B USD64.9%
Operating expenses7.7B USD53.7%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin fell in 5 years from −1.8% to −18.6%.

Gross marginOperating marginNet margin
  1. Fiscal year 2018: Gross margin 35.0% · Operating margin 7.9% · Net margin 3.1%
  2. Fiscal year 2019: Gross margin 33.9% · Operating margin 6.2% · Net margin 0.1%
  3. Fiscal year 2020: Gross margin 31.8% · Operating margin −1.8% · Net margin −5.6%
  4. Fiscal year 2021: Gross margin 31.2% · Operating margin −0.2% · Net margin −7.1%
  5. Fiscal year 2022: Gross margin 40.0% · Operating margin 9.9% · Net margin 12.8%
  6. Fiscal year 2023: Gross margin 41.7% · Operating margin 5.0% · Net margin 0.4%
  7. Fiscal year 2024: Gross margin 38.2% · Operating margin 0.1% · Net margin −4.3%
  8. Fiscal year 2025: Gross margin 35.1% · Operating margin −18.6% · Net margin −24.6%

Returns

Return on equity fell in 5 years from −2.9% to −23.9%.

Return on equityReturn on assets
  1. Fiscal year 2018: Return on equity 2.9% · Return on assets not available
  2. Fiscal year 2019: Return on equity not available · Return on assets not available
  3. Fiscal year 2020: Return on equity −2.9% · Return on assets −1.1%
  4. Fiscal year 2021: Return on equity −6.2% · Return on assets −2.3%
  5. Fiscal year 2022: Return on equity 9.9% · Return on assets 4.2%
  6. Fiscal year 2023: Return on equity 0.3% · Return on assets 0.1%
  7. Fiscal year 2024: Return on equity −3.4% · Return on assets −1.5%
  8. Fiscal year 2025: Return on equity −23.9% · Return on assets −9.5%

Equity and long-term debt

The equity ratio rose in 5 years from 37.3% to 39.6%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2018: Equity 12.2B USD · Long-term debt not available
  2. Fiscal year 2019: Equity 0.0 USD · Long-term debt 0.0 USD
  3. Fiscal year 2020: Equity 23.0B USD · Long-term debt 22.4B USD
  4. Fiscal year 2021: Equity 20.5B USD · Long-term debt 19.7B USD
  5. Fiscal year 2022: Equity 21.1B USD · Long-term debt 18.0B USD
  6. Fiscal year 2023: Equity 20.5B USD · Long-term debt 16.2B USD
  7. Fiscal year 2024: Equity 18.6B USD · Long-term debt 14.0B USD
  8. Fiscal year 2025: Equity 14.7B USD · Long-term debt 12.5B USD

Liquidity (current ratio)

The current ratio rose in 5 years from 1.22 to 1.38.

Current ratio
  1. Fiscal year 2018: Current ratio not available
  2. Fiscal year 2019: Current ratio not available
  3. Fiscal year 2020: Current ratio 1.22
  4. Fiscal year 2021: Current ratio 1.10
  5. Fiscal year 2022: Current ratio 1.58
  6. Fiscal year 2023: Current ratio 1.67
  7. Fiscal year 2024: Current ratio 1.65
  8. Fiscal year 2025: Current ratio 1.38

Cash flow

Free cash flow rose in 5 years from 988.8M USD to 1.9B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2018: Operating cash flow 2.3B USD · Capital expenditure 252.1M USD · Free cash flow 2.1B USD
  2. Fiscal year 2019: Operating cash flow 1.8B USD · Capital expenditure 213.2M USD · Free cash flow 1.6B USD
  3. Fiscal year 2020: Operating cash flow 1.2B USD · Capital expenditure 243.0M USD · Free cash flow 988.8M USD
  4. Fiscal year 2021: Operating cash flow 3.0B USD · Capital expenditure 457.2M USD · Free cash flow 2.6B USD
  5. Fiscal year 2022: Operating cash flow 3.0B USD · Capital expenditure 406.0M USD · Free cash flow 2.5B USD
  6. Fiscal year 2023: Operating cash flow 2.8B USD · Capital expenditure 377.0M USD · Free cash flow 2.4B USD
  7. Fiscal year 2024: Operating cash flow 2.3B USD · Capital expenditure 326.0M USD · Free cash flow 2.0B USD
  8. Fiscal year 2025: Operating cash flow 2.3B USD · Capital expenditure 378.8M USD · Free cash flow 1.9B USD

Share count

The share count rose in 5 years by 133.7% – more new shares were issued than repurchased (dilution).

Diluted share count
  1. Fiscal year 2018: Diluted share count 516.5M
  2. Fiscal year 2019: Diluted share count 516.5M
  3. Fiscal year 2020: Diluted share count 601.2M
  4. Fiscal year 2021: Diluted share count 1.2B
  5. Fiscal year 2022: Diluted share count 1.2B
  6. Fiscal year 2023: Diluted share count 1.2B
  7. Fiscal year 2024: Diluted share count not available
  8. Fiscal year 2025: Diluted share count not available

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

Dividend per share

The dividend per share rose in 4 years from 0.33 USD to 0.48 USD.

VTRS USD per share
  1. Fiscal year 2018: VTRS not available
  2. Fiscal year 2019: VTRS not available
  3. Fiscal year 2020: VTRS not available
  4. Fiscal year 2021: VTRS 0.33 USD
  5. Fiscal year 2022: VTRS 0.48 USD
  6. Fiscal year 2023: VTRS 0.48 USD
  7. Fiscal year 2024: VTRS 0.48 USD
  8. Fiscal year 2025: VTRS 0.48 USD

Payout ratio (earnings)

VTRS
  1. Fiscal year 2018: VTRS not available
  2. Fiscal year 2019: VTRS not available
  3. Fiscal year 2020: VTRS not available
  4. Fiscal year 2021: VTRS not available
  5. Fiscal year 2022: VTRS 28.1%
  6. Fiscal year 2023: VTRS not available
  7. Fiscal year 2024: VTRS not available
  8. Fiscal year 2025: VTRS not available

Payout ratio (free cash flow)

The payout ratio (free cash flow) rose in 4 years from 15.8% to 29.8%.

VTRS
  1. Fiscal year 2018: VTRS not available
  2. Fiscal year 2019: VTRS not available
  3. Fiscal year 2020: VTRS not available
  4. Fiscal year 2021: VTRS 15.8%
  5. Fiscal year 2022: VTRS 23.2%
  6. Fiscal year 2023: VTRS 24.4%
  7. Fiscal year 2024: VTRS 29.7%
  8. Fiscal year 2025: VTRS 29.8%

Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The dividend per share was never cut as far as our annual data goes (4 years in a row).

Years without a cut
at least 4
as far as the data goes
Growth per year (5 yrs)
–
no comparable dividend 5 years ago
Coverage by free cash flow
–
free cash flow or share count not reported

You can see the dividend yield and shareholder yield (based on the price) with a free account. Sign up free

More depth

Years without a cut: in a row up to fiscal year 2025, dividend per share according to the SEC, adjusted for stock splits; only 1% less than the year before counts as a cut, also for variable dividends; a special dividend in the prior year does not. If the dividend per share falls while the total paid rises, the run ends as “unclear”. “At least” is shown only if our data ends earlier.

Shareholder yield: dividends paid plus share repurchases minus proceeds from new shares according to the cash flow statement of the last fiscal year, divided by today’s market value. Missing repurchases or new shares count as 0; without reported dividend or repurchase payments (among others for many stocks of the extended selection) there is no value. Describes the reported figures – not investment advice.

History, payout ratios and returns per year

As of fiscal year 2025 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

There is no comparison for the P/E: the last fiscal year ended with a loss.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
0.48 USD · Fiscal year 2025
Dividend growth per year
3 y 0.0%5 y –10 y –
Payout ratio
of earnings – of free cash flow 30%
To shareholders (5 years)
3.8B USD 27% through repurchases
Share count over 5 years
+133.7% more shares – dilution

Dividend per share

The dividend per share rose in 4 years from 0.33 USD to 0.48 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2018: Dividend per share not available
  2. Fiscal year 2019: Dividend per share not available
  3. Fiscal year 2020: Dividend per share not available
  4. Fiscal year 2021: Dividend per share 0.33 USD
  5. Fiscal year 2022: Dividend per share 0.48 USD
  6. Fiscal year 2023: Dividend per share 0.48 USD
  7. Fiscal year 2024: Dividend per share 0.48 USD
  8. Fiscal year 2025: Dividend per share 0.48 USD

Payout ratios

Last reported for fiscal year 2022.

Payout ratio (earnings)Payout ratio (free cash flow) Ratios above 500% hidden (earnings or free cash flow close to zero).
  1. Fiscal year 2018: Payout ratio (earnings) not available · Payout ratio (free cash flow) not available
  2. Fiscal year 2019: Payout ratio (earnings) not available · Payout ratio (free cash flow) not available
  3. Fiscal year 2020: Payout ratio (earnings) not available · Payout ratio (free cash flow) not available
  4. Fiscal year 2021: Payout ratio (earnings) not available · Payout ratio (free cash flow) 15.8%
  5. Fiscal year 2022: Payout ratio (earnings) 28.1% · Payout ratio (free cash flow) 23.2%
  6. Fiscal year 2023: Payout ratio (earnings) not available · Payout ratio (free cash flow) 24.4%
  7. Fiscal year 2024: Payout ratio (earnings) not available · Payout ratio (free cash flow) 29.7%
  8. Fiscal year 2025: Payout ratio (earnings) not available · Payout ratio (free cash flow) 29.8%

What goes back to shareholders

Over 5 years, 3.8B USD went back to shareholders, 27% of it through share repurchases. That is 33% of the free cash flow of those years. This was offset by new shares issued for 11.5M USD (including employee plans).

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD Dividends partly reported as declared rather than paid.
  1. Fiscal year 2018: Dividends paid not available · Share repurchases 432.0M USD · New shares issued (including employee plans) not available · Free cash flow 2.1B USD
  2. Fiscal year 2019: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 1.6B USD
  3. Fiscal year 2020: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 988.8M USD
  4. Fiscal year 2021: Dividends paid 403.3M USD · Share repurchases 0.0 USD · New shares issued (including employee plans) 0.0 USD · Free cash flow 2.6B USD
  5. Fiscal year 2022: Dividends paid 591.8M USD · Share repurchases 0.0 USD · New shares issued (including employee plans) 3.3M USD · Free cash flow 2.5B USD
  6. Fiscal year 2023: Dividends paid 590.6M USD · Share repurchases 250.0M USD · New shares issued (including employee plans) 3.1M USD · Free cash flow 2.4B USD
  7. Fiscal year 2024: Dividends paid 586.7M USD · Share repurchases 250.0M USD · New shares issued (including employee plans) 2.5M USD · Free cash flow 2.0B USD
  8. Fiscal year 2025: Dividends paid 577.1M USD · Share repurchases 500.5M USD · New shares issued (including employee plans) 2.6M USD · Free cash flow 1.9B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Viatris next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison VTRS, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
AMGN Amgen 36.8B USD +7.6%67.2%24.7%21.0%89.1%9.6%22.0%7/9
MDT Medtronic 36.4B USD +3.8%65.0%17.8%13.2%9.7%53.2%14.9%7/9
GILD Gilead Sciences 29.4B USD +3.6%78.8%34.0%28.9%37.5%38.5%32.1%8/9
SYK Stryker Corporation 25.1B USD +11.8%64.0%19.5%12.9%14.5%46.9%17.1%6/9
DHR Danaher Corporation 24.6B USD +2.0%59.1%19.1%14.7%6.9%62.9%21.4%7/9
REGN Regeneron Pharmaceuticals 14.3B USD +11.0%–24.9%31.4%14.4%77.1%28.4%–
VTRS Viatris this stock 14.3B USD +3.7%35.1%−18.6%−24.6%−23.9%39.6%13.5%–
VRTX Vertex Pharmaceuticals 12.0B USD +14.1%86.2%34.8%32.9%21.2%72.8%26.6%–
ISRG Intuitive Surgical 10.1B USD +18.2%66.0%29.3%28.4%16.0%87.1%24.7%–
Median of the sector 27 symbols 44.3B USD +8.4%67.2%17.8%13.2%13.6%38.5%14.7%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector VTRS next to REGN – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+3.7% per year, last 5 years

Sector Health Care: median +8.5% (25 symbols)

What does this mean? Revenue: over 5 years it grew by 3.7% per year on average, but more slowly than the median company in the sector (+8.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light gray: not computable

– per year, last 5 years

Sector Health Care: median +5.5% (20 symbols)

per share: not computable (loss in the first or last year)

What does this mean? There was a loss in the first or last year. An annual growth rate cannot be calculated meaningfully then.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light red: Loss

−24.6% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue there was no profit but a loss of 24.58 USD. Five years ago the margin was −5.6%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light yellow: higher than sector

0.85 latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? For every 1 USD of equity there is 0.85 USD of financial debt – more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light red: despite a loss

– Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? The company paid a dividend in the last fiscal year although there was a loss per share; it is paid from cash flow, from reserves or with new debt.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light red: 4 loss years

4 of 8 fiscal years with a profit

What does this mean? In 4 of the last 8 fiscal years the bottom line showed a profit. 4 years ended with a loss.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
14.3B USD
Revenue vs. prior year
−3.0%
Net income (FY)
−3.5B USD
Net income vs. prior year
–
EPS (FY)
-3.00 USD
Superinvestors holding
4 of 26
Fiscal year to Dec 31, 2025 · 10-K filed Feb 26, 2026 · Balance sheet Sep 30, 2026 (filed Nov 5, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 14.3B−3.5B −24.6% −3.00 0.48 –
2024Dec 31, 2024 14.7B−634.2M −4.3% −0.53 0.48 –
2023Dec 31, 2023 15.4B54.7M 0.4% 0.05 0.48 960%
2022Dec 31, 2022 16.3B2.1B 12.8% 1.71 0.48 28%
2021Dec 31, 2021 17.9B−1.3B −7.1% −1.05 0.33 –
2020Dec 31, 2020 11.9B−669.9M −5.6% −1.11 – –
2019Dec 31, 2019 11.5B16.8M 0.1% 0.03 – –
2018Dec 31, 2018 11.4B352.5M 3.1% 0.68 – –
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 30, 2026 3.7B– – −0.28 0.12 –
Q2/26Jun 30, 2026 3.8B– – −0.10 0.12 –
Q1/26Mar 31, 2026 3.5B– – 0.15 0.12 80%
Q4/25*Dec 31, 2025 3.7B– – – 0.12 –
Q3/25Sep 30, 2025 3.8B– – −0.11 0.12 –
Q2/25Jun 30, 2025 3.6B– – 0.00 0.12 –
Q1/25Mar 31, 2025 3.3B– – −2.55 0.12 –
Q4/24*Dec 31, 2024 3.5B– – – 0.12 –
Q3/24Sep 30, 2024 3.8B– – 0.08 0.12 150%
Q2/24Jun 30, 2024 3.8B– – −0.27 0.12 –
Q1/24Mar 31, 2024 3.7B– – 0.09 0.12 133%
Q4/23*Dec 31, 2023 3.8B– – – 0.12 –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $00 people $0
6 months $00 people $809.8K1 person −$809.8K
12 months $00 people $1.1M1 person −$1.1M

Latest transactions

  • Jun 25, 2026 Campbell Paul Officer Open-market sale · 10b5-1 plan 50,076 shares · $809.8K · SEC
  • Mar 23, 2026 Campbell Paul Officer Open-market sale 21,350 shares · $283.5K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold Viatris?

All superinvestor portfolios

4 of 26 tracked superinvestors report a position.

Superinvestors with a position in Viatris, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
David Einhorn Greenlight Capital 2.1% +54.9% increased Q3 2026
Bridgewater Associates 0.2% +26.7% increased Q3 2026
Paul Tudor Jones Tudor Investment Corp < 0.1% new Q3 2026
Renaissance Technologies < 0.1% new Q3 2026

Sold out in the latest quarter: Steve Cohen.

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score –

We do not calculate a trend score for symbols in the extended universe.

Volatility and trend strength

ADX 14 (trend strength)–
Price change 60 days–

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.

Posts

No posts on VTRS yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: VTRS

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close